Cargando…

Rasagiline for sleep disorders in patients with Parkinson’s disease: a prospective observational study

INTRODUCTION: Rasagiline is a selective, irreversible monoamine oxidase B inhibitor that ameliorates the symptoms of Parkinson’s disease (PD) by inhibiting striatal dopamine metabolism. There is also evidence that monoamine oxidase B inhibitors increase melatonin levels in the pineal gland and may h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schettino, Carla, Dato, Clemente, Capaldo, Guglielmo, Sampaolo, Simone, Di Iorio, Giuseppe, Melone, Mariarosa AB
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5047735/ https://www.ncbi.nlm.nih.gov/pubmed/27729794 http://dx.doi.org/10.2147/NDT.S116476

Ejemplares similares

Late adult-onset adrenomyeloneuropathy evolving with atypical severe frontal lobe syndrome: Importance of neuroimaging
por: Dato, Clemente, et al.
Publicado: (2018)

Foix-Chavany-Marie syndrome in a 17-year-old female with congenital cytomegalovirus infection
por: Conforti, Renata, et al.
Publicado: (2014)

Synergistic Interplay between Curcumin and Polyphenol-Rich Foods in the Mediterranean Diet: Therapeutic Prospects for Neurofibromatosis 1 Patients
por: Esposito, Teresa, et al.
Publicado: (2017)

Rasagiline Withdrawal Syndrome in Parkinson’s Disease
por: Solla, Paolo, et al.
Publicado: (2022)

Rasagiline in treatment of Parkinson’s disease
por: Nayak, Lakshmi, et al.
Publicado: (2008)

The role of rasagiline in the treatment of Parkinson’s disease
por: Leegwater-Kim, Julie, et al.
Publicado: (2010)

Bioactive Phenolic Compounds in the Modulation of Central and Peripheral Nervous System Cancers: Facts and Misdeeds
por: Perrone, Lorena, et al.
Publicado: (2020)

Rasagiline, sleep quality and well-being in Parkinson’s disease: a pilot study
por: Mutti, Carlotta, et al.
Publicado: (2022)

Adjunctive therapy in Parkinson’s disease: the role of rasagiline
por: Gaines, Kathryn D, et al.
Publicado: (2012)

Giant thrombosed intracavernous carotid artery aneurysm presenting as Tolosa–Hunt syndrome in a patient harboring a new pathogenic neurofibromatosis type 1 mutation: a case report and review of the literature
por: Conforti, Renata, et al.
Publicado: (2014)

Understanding the Biological Activities of Vitamin D in Type 1 Neurofibromatosis: New Insights into Disease Pathogenesis and Therapeutic Design
por: Riccardi, Claudia, et al.
Publicado: (2020)

Nanoparticle-Guided Brain Drug Delivery: Expanding the Therapeutic Approach to Neurodegenerative Diseases
por: Riccardi, Claudia, et al.
Publicado: (2021)

From a Parkinson's disease expert: Rasagiline and the Future of Therapy
por: Lakhan, Shaheen E
Publicado: (2007)

Role of rasagiline in treating Parkinson’s disease: Effect on disease progression
por: Malaty, Irene A, et al.
Publicado: (2009)

Rasagiline – a novel MAO B inhibitor in Parkinson’s disease therapy
por: Lecht, Shimon, et al.
Publicado: (2007)

Rasagiline and Rapid Symptomatic Motor Effect in Parkinson’s Disease: Review of Literature
por: Pistacchi, Michele, et al.
Publicado: (2013)

The Autophagy Signaling Pathway: A Potential Multifunctional Therapeutic Target of Curcumin in Neurological and Neuromuscular Diseases
por: Perrone, Lorena, et al.
Publicado: (2019)

Systemic Delivery of Recombinant Brain Derived Neurotrophic Factor (BDNF) in the R6/2 Mouse Model of Huntington’s Disease
por: Giampà, Carmela, et al.
Publicado: (2013)

Correction: Systemic Delivery of Recombinant Brain Derived Neurotrophic Factor (BDNF) in the R6/2 Mouse Model of Huntington's Disease
por: Giampà, Carmela, et al.
Publicado: (2016)

Neuroacanthocytosis Syndromes in an Italian Cohort: Clinical Spectrum, High Genetic Variability and Muscle Involvement
por: Vaisfeld, Alessandro, et al.
Publicado: (2021)

Rasagiline Ameliorates Olfactory Deficits in an Alpha-Synuclein Mouse Model of Parkinson's Disease
por: Petit, Géraldine H., et al.
Publicado: (2013)

Comparison of Selegiline and Rasagiline Therapies in Parkinson Disease: A Real-life Study
por: Peretz, Chava, et al.
Publicado: (2016)

Safety and Effectiveness of Rasagiline in Chinese Patients with Parkinson’s Disease: A Prospective, Multicenter, Non-interventional Post-marketing Study
por: Su, Wen, et al.
Publicado: (2023)

Rasagiline does not exacerbate autonomic blood pressure dysregulation in early or mild Parkinson’s disease
por: Oka, Hisayoshi, et al.
Publicado: (2021)

Rasagiline as Adjunct to Levodopa for Treatment of Parkinson's Disease: A Systematic Review and Meta-Analysis
por: Kano, Osamu, et al.
Publicado: (2022)

Curcumin modulation of L-dopa and rasagiline-induced neuroprotection in rotenone model of Parkinson’s disease
por: El-Shamarka, Marwa El-Sayed, et al.
Publicado: (2023)

No synergism between bis(propyl)-cognitin and rasagiline on protecting dopaminergic neurons in Parkinson's disease mice
por: Zheng, Cheng-you, et al.
Publicado: (2016)

Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson’s disease
por: Hattori, Nobutaka, et al.
Publicado: (2019)

Linezolid and Rasagiline – A culprit for serotonin syndrome
por: Hisham, Mohamed, et al.
Publicado: (2016)

Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson’s Disease with Neuroprotective Potential
por: Finberg, John P.M.
Publicado: (2010)

Preparation and evaluation of injectable Rasagiline mesylate dual-controlled drug delivery system for the treatment of Parkinson’s disease
por: Jiang, Ying, et al.
Publicado: (2017)

Adjunct rasagiline to treat Parkinson’s disease with motor fluctuations: a randomized, double-blind study in China
por: Zhang, Zhenxin, et al.
Publicado: (2018)

Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson’s disease
por: Hattori, Nobutaka, et al.
Publicado: (2019)

Engineering of Reductive Aminases for Asymmetric Synthesis of Enantiopure Rasagiline
por: Zhang, Kai, et al.
Publicado: (2021)

A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson’s disease patients
por: Barone, P, et al.
Publicado: (2015)

Efficacy of rasagiline and selegiline in Parkinson’s disease: a head-to-head 3-year retrospective case–control study
por: Cereda, Emanuele, et al.
Publicado: (2017)

Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia
por: Matthews, Dawn C., et al.
Publicado: (2021)

Striking Neurochemical and Behavioral Differences in the Mode of Action of Selegiline and Rasagiline
por: Harsing, Laszlo G., et al.
Publicado: (2023)

Multi Target Neuroprotective and Neurorestorative Anti-Parkinson and Anti-Alzheimer Drugs Ladostigil and M30 Derived from Rasagiline
por: Youdim, Moussa B.H.
Publicado: (2013)

Erratum to: Efficacy of rasagiline and selegiline in Parkinson’s disease: a head-to-head 3-year retrospective case–control study
por: Cereda, Emanuele, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1hm66jj5q72hevc43n62cul4lm